Exhibit 11.1 Triangle Pharmaceuticals, Inc. (A Development Stage Company) Computation of Net Loss Per Common Share (In thousands, except per share amounts) Three Months Nine Months Three Months Nine Months Ended Ended Ended Ended September 30, September 30, September 30, September 30, 1998 1998 1997(1) 1997(1) ------------- ------------- ------------- ------------- Historical weighted average shares outstanding ....................... 24,058 22,511 19,736 18,492 --------- --------- --------- --------- Shares used in computing net loss per common share ...................... 24,058 22,511 19,736 18,492 ========= ========= ========= ========= Net Loss ............................ $ (15,619) $ (46,283) $ (18,214) $ (27,375) ========= ========= ========= ========= Basic and diluted net loss per common share ............................. $ (0.65) $ (2.06) $ (0.92) $ (1.48) ========= ========= ========= ========= - ---------- (1) The weighted average shares outstanding used in the calculation of net loss per common share have been restated to reflect the adoption of Statement of Financial Accounting Standards No. 128, "Earnings Per Share" and its interpretation by Securities and Exchange Staff Accounting Bulletin No. 98.